Prevention of HIV/AIDS

Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates

Retrieved on: 
Monday, June 7, 2021
Medicine, Clinical medicine, Health, Leronlimab, Prevention of HIV/AIDS, HIV/AIDS, Pre-exposure prophylaxis, HIV, CCR5 receptor antagonist

Sacha and Ndhlovu for their contributions to this important study and very much look forward to the future PrEP trial to prevent human infection of the AIDs virus.

Key Points: 
  • Sacha and Ndhlovu for their contributions to this important study and very much look forward to the future PrEP trial to prevent human infection of the AIDs virus.
  • PrEP drugs currently available can lead to adverse side effects such as kidney and bone problems, side effects we have not seen with leronlimab.
  • The potential use of leronlimab in multiple therapeutic indications is exciting (i.e., HIV, NASH, cancer, COVID-19).
  • Leronlimab does not work on other strains of HIV (for example X4), however R5 is the most dominant strain of HIV.

Global HIV Pre-Exposure Prophylaxis (HIV PrEP) Disease Analysis Report 2021: Uptake of PrEP is Expected to Continue Following Positive European Reimbursement Decisions - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, Pharmaceutical, Hepatotoxins, Medicine, Clinical medicine, Prevention of HIV/AIDS, HIV/AIDS, Pre-exposure prophylaxis, Emtricitabine/tenofovir, Management of HIV/AIDS, Prep, Neutralizing antibody, Zidovudine

The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.
  • However, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as Gilead's marketing efforts.
  • Within the EU and UK, Truvada is the only approved agent for PrEP but generates minimal sales due to generic competition since July 2017.
  • There are currently six agents in clinical development for pharmacological PrEP, comprising five antiretrovirals and a single broadly neutralizing antibody.

CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19

Retrieved on: 
Tuesday, June 1, 2021
Leronlimab, Retroviridae, Prevention of HIV/AIDS, HIV/AIDS, Drugs, Sexually transmitted diseases and infections, Medical specialties, Management of HIV/AIDS, HIV, Triple-negative breast cancer, CCR5 receptor antagonist

Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.

Key Points: 
  • Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.
  • Filipinos can get more information on how to access leronlimab in the Philippines by contacting CytoDyns local distribution partner Chiral Pharma Corporation.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • Leronlimab does not work on other strains of HIV (for example X4), however R5 is the most dominant strain of HIV.

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

Retrieved on: 
Thursday, May 27, 2021
Leronlimab, Drugs, Hepatotoxins, Medical specialties, Health, Prevention of HIV/AIDS, CCR5 receptor antagonist

Once approved by ANVISA, the Phase 3 trials will be conducted by Albert Einstein Israelite Hospital, an Academic Research Organization in Brazil.

Key Points: 
  • Once approved by ANVISA, the Phase 3 trials will be conducted by Albert Einstein Israelite Hospital, an Academic Research Organization in Brazil.
  • The COVID-19 trials in Brazil are intended to provide ANVISA with the requisite data to consider advancing the availability of leronlimab to thousands of Brazilians infected with COVID-19.
  • CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis.
  • CytoDyn successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization

Retrieved on: 
Wednesday, May 19, 2021
Biotechnology, General Health, Health, Other Health, Product management, Marketing, Articles, Business, Pre-exposure prophylaxis, Prevention of HIV/AIDS, Commercialization, Product marketing

b"Qvella , a diagnostics company that aims to reduce the time to results in the diagnosis of infections, today announced that it has appointed Richard Brock as VP of Global Marketing.

Key Points: 
  • b"Qvella , a diagnostics company that aims to reduce the time to results in the diagnosis of infections, today announced that it has appointed Richard Brock as VP of Global Marketing.
  • In this role, he will lead the imminent commercialization of Qvella\xe2\x80\x99s FAST-Prep\xe2\x84\xa2 product for Positive Blood Culture (PBC) processing.
  • He will be responsible for the company\xe2\x80\x99s go-to-market and product strategies, building and supporting sales enablement tools, and increasing awareness of the Qvella brand.
  • Qvella has 90 employees working from its headquarters in Richmond Hill, Ontario as well as offices in Carlsbad, California and Mechelen, Belgium.

Sexual and Reproductive Heath, Rights and Justice Organizations Applaud Introduction of Legislations to Improve the Health and Well-Being of Young People

Retrieved on: 
Tuesday, May 18, 2021
Midwifery, Sexuality and society, Articles, Prevention of HIV/AIDS, Human sexuality, Harm reduction, Sex education, Reproductive health, Health, Comprehensive sex education, Reproductive justice

Together, these measures will help empower young people to make their own decisions about their bodies and lives.\n"All young people no matter who they are or where they live deserve high-quality, medically-accurate and inclusive sex education.

Key Points: 
  • Together, these measures will help empower young people to make their own decisions about their bodies and lives.\n"All young people no matter who they are or where they live deserve high-quality, medically-accurate and inclusive sex education.
  • "High-quality sex education can have an immense impact on a young person\'s life, and we must continue to break down the barriers for young people to access this information.
  • "\nThe introduction of this legislation coincides with Sex Ed For All Month , a national effort led by a coalition of sexual and reproductive health, rights and justice organizations committed to ensuring equitable and accessible sex education for all young people.
  • Throughout May, the coalition pledges to ensure all young people have equitable access to the sex education and sexual health care they deserve.

CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Leronlimab, Breast cancer, Biology, Drugs, Triple-negative breast cancer, Prevention of HIV/AIDS, HIV/AIDS, Biomarker, Management of HIV/AIDS, CCR5 receptor antagonist

We are very excited for the opportunity to receive our first approval in multiple countries in great need of leronlimab.

Key Points: 
  • We are very excited for the opportunity to receive our first approval in multiple countries in great need of leronlimab.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC.
  • CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3).

Adameve.com Hosts Clubhouse Chat with Sex Therapist Brittany Steffen and Sex Educator Amanda Ladd

Retrieved on: 
Thursday, May 13, 2021
Software, Harm reduction, Prevention of HIV/AIDS, Sex education, Sexuality and society, Clubhouse, Articles, Computing

On Thursday evenings at 8 pm Eastern time, listeners will be able to join in the fun with Sex Therapist Brittany Steffen and Sex Educator Amanda Ladd.

Key Points: 
  • On Thursday evenings at 8 pm Eastern time, listeners will be able to join in the fun with Sex Therapist Brittany Steffen and Sex Educator Amanda Ladd.
  • Scheduled to run through Thursday, June 10, this weekly chat can be accessed by Clubhouse members here: https://www.joinclubhouse.com/event/Prn4y5N5 .\nChad Davis, Marketing Director for adameve.com, says, "Clubhouse is a natural for Adam & Eve.
  • Our \'Adult Sex Ed\' chat is the perfect forum for attendees to listen and ask the sex experts questions of their own.
  • "\n"We\'ve enjoyed discussing meeting our Clubhouse visitors and hearing what they have to say about sex," says Brittany Steffen, Marriage and Family Therapist, MS, LMFT.

Gritstone Reports First Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 6, 2021
Vaccines, Biotechnology, Prevention of HIV/AIDS, Life sciences, Gilead Sciences, HIV vaccine development, Articles

\xe2\x80\x9cWe expect this activity level to extend into the rest of the year.

Key Points: 
  • \xe2\x80\x9cWe expect this activity level to extend into the rest of the year.
  • We are continuing patient dosing and follow-up in our GRANITE program and will be submitting these data for presentation at ESMO.
  • Additionally, we expect to have data from our CORAL COVID-19 program available later this year.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Health, Pharmacy, Clinical pharmacology, Prevention of HIV/AIDS, Medical terminology, Adherence, Health care quality, Digital pill, Management of HIV/AIDS, Medication, Pill organizer

b'GAINESVILLE, Fla. & BOSTON, May 4, 2021 /PRNewswire/ -- Digital health company, etectRx , Inc., today announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV.

Key Points: 
  • b'GAINESVILLE, Fla. & BOSTON, May 4, 2021 /PRNewswire/ -- Digital health company, etectRx , Inc., today announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV.
  • The study, dubbed "MyTPill," will assess patient adherence using two electronic adherence tracking technologies: the ID-Cap System from etectRx and an electronic pill box.
  • The FDA-cleared ID-Cap System uniquely addresses the issue with patient adherence to (oral) medication.
  • The accurate, flexible and elegant digital pill system allows pharmaceutical companies to rethink approaches to medication adherence, innovate with confidence, and accelerate patient outcomes.